Press Releases

Oxford Biomedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease

Oxford, UK – 25 October 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, notes that its partner, Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, has announced the successful dosing of the first patient in… Read More

Oxford Biomedica announces additional details of its strategic alliance with Orchard Therapeutics

London, UK – 5 October 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces additional details of its strategic alliance with Orchard Therapeutics, as disclosed in the public filing by Orchard Therapeutics on a Form F-1 Registration Statement ahead of… Read More

Oxford Biomedica announces further capacity expansion with new facility

Lentiviral vector bioprocessing market expected to grow to $800m by 2026 Oxford BioMedica adds fourth facility in Oxford allowing the Group to target 25% to 30% of global lentiviral vector bioprocessing market (excluding milestones and royalties) Oxford, UK – 13 September 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica”… Read More

Interim results for the six months ended 30 June 2018

Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2018. FINANCIAL HIGHLIGHTSGross income growth of 118% to £36.0 million (H1 2017: £15.7 million) Operating EBITDA… Read More

Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval

London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of paediatric and… Read More

Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis

Oxford, UK – 6 August 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into a process development collaboration agreement with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations to develop a long-term… Read More

Kymriah (tisagenlecleucel, formerly CTL019) receives positive CHMP opinion for the treatment of two aggressive blood cancers, marking important milestone for patients in Europe

London, UK – 29 June 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of… Read More

Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for Oxford Biomedica-102 for the Treatment of Parkinson’s Disease

~       Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below) Oxford, UK– 06 June 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into an exclusive worldwide licensing agreement… Read More

Share Consolidation

Oxford BioMedica plc (“Oxford BioMedica”, “the Company” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announced on 4 May 2018 a proposed share capital Consolidation of the existing ordinary share capital of the Company. The effect of the proposed Consolidation will be to reduce the number of… Read More

Proposed placing to raise approximately £20.5 million

Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy

Oxford, UK– 15 February 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has completed a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia. The agreement… Read More

Oxford BioMedica announces £3 million grant awarded by Innovate UK

London, UK – 23 January 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, has announced it that has been awarded a £3 million grant by the UK’s innovation agency, Innovate UK, to support the UK’s efforts to produce viral vectors and… Read More